Trigeminal neuralgia management after microvascular decompression surgery: two case reports.
Carbamazepine
Case Reports
Gabapentin
Microvascular Decompression Surgery
Trigeminal Neuralgia
Journal
Journal of dental anesthesia and pain medicine
ISSN: 2383-9309
Titre abrégé: J Dent Anesth Pain Med
Pays: Korea (South)
ID NLM: 101690691
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
13
09
2020
revised:
25
11
2020
accepted:
15
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
ppublish
Résumé
Trigeminal neuralgia (TN) involves chronic neuropathic pain, characterized by attacks of repeating short episodes of unilateral shock-like pain, which are abrupt in onset and termination. Anticonvulsants, such as carbamazepine, are the gold standard first-line drugs for pharmacological treatment. Microvascular decompression (MVD) surgery is often the course of action if pharmacological management with anticonvulsants is unsuccessful. MVD surgery is an effective therapy in approximately 83% of cases. However, persistent neuropathic pain after MVD surgery may require reintroduction of pharmacotherapy. This case report presents two patients with persistent pain after MVD requiring reintroduction of pharmacological therapy. Although MVD is successful for patients with failed pharmacological management, it is an invasive procedure and requires hospitalization of the patient. About one-third of patients suffer from recurrent TN after MVD. Often, alternative treatment protocols, including the reintroduction of medications, may be necessary to achieve improvement. This case report presents two cases of post-MVD recurrent pain. Further research is lacking on the success rates of subsequent medication therapy after MVD has proven less effective in managing TN.
Identifiants
pubmed: 33409369
doi: 10.17245/jdapm.2020.20.6.403
pmc: PMC7783379
doi:
Types de publication
Case Reports
Langues
eng
Pagination
403-408Informations de copyright
Copyright © 2020 Journal of Dental Anesthesia and Pain Medicine.
Références
Pain Med. 2017 Sep 1;18(9):1824-1826
pubmed: 28340099
J Dent (Shiraz). 2014 Sep;15(3):140-6
pubmed: 25191664
Arch Dis Child. 2000 Apr;82(4):311-5
pubmed: 10735840
Neurosurgery. 2020 Feb 1;86(2):182-190
pubmed: 30892607
Neurology. 2008 Oct 7;71(15):1183-90
pubmed: 18716236
Yonsei Med J. 2020 Oct;61(10):875-879
pubmed: 32975062
BJGP Open. 2020 Dec 1;:
pubmed: 33172853
Rev Neurosci. 2016 Oct 1;27(7):739-743
pubmed: 27383870
J Pharm Pract. 2020 Sep 29;:897190020961229
pubmed: 32990167
Neuroepidemiology. 1991;10(5-6):276-81
pubmed: 1798430
BMJ. 1995 Oct 21;311(7012):1047-52
pubmed: 7580659
Anaesthesia. 2002 May;57(5):451-62
pubmed: 11966555
J Midlife Health. 2015 Jan-Mar;6(1):10-5
pubmed: 25861202
World Neurosurg. 2019 Aug;128:e556-e561
pubmed: 31071444
Turk Neurosurg. 2018;28(1):88-93
pubmed: 27593849
Pharmacogenomics. 2008 Oct;9(10):1543-6
pubmed: 18855540
Clin Ther. 2003 Jan;25(1):81-104
pubmed: 12637113
CNS Drugs. 2014 Jun;28(6):491-6
pubmed: 24760436
Lancet Neurol. 2020 Sep;19(9):784-796
pubmed: 32822636
J Pain. 2002 Apr;3(2):137-42
pubmed: 14622800